Transport by SLC5A8 with subsequent inhibition of histone deacetylase 1 (HDAC1) and HDAC3 underlies the antitumor activity of 3-bromopyruvate

Cancer

Volumn 115, Issue 20, 2009, Pages 4655-4666

  Thangaraju, Muthusamy ^a   Karunakaran, Senthil K ^a   Itagaki, Shiro ^a   Gopal, Elangovan ^a   Elangovan, Selvakumar ^a   Prasad, Puttur D ^a   Ganapathy, Vadivel ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

3 bromopyruvate; Apoptosis; Breast cancer; Butyrate; Glycolysis; HDAC inhbitiors; Histone deacetylases; Pyruvate; SLC5A8; SMCT1

Indexed keywords

BROMOPYRUVIC ACID; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 3; PYRUVIC ACID; SODIUM GLUCOSE COTRANSPORTER; SODIUM GLUCOSE COTRANSPORTER 8; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL DEATH; CELL LYSATE; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; DNA METHYLATION; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; MAMMAL CELL; NONHUMAN; OOCYTE; PRIORITY JOURNAL; WESTERN BLOTTING; XENOPUS LAEVIS;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOLOGICAL TRANSPORT; BREAST NEOPLASMS; CATION TRANSPORT PROTEINS; CELL LINE; CELL LINE, TUMOR; ENZYME INHIBITORS; HISTONE DEACETYLASE 1; HISTONE DEACETYLASES; HUMANS; MICE; PYRUVATES; RATS; RECOMBINANT PROTEINS; RETINAL PIGMENT EPITHELIUM; TRANSFECTION; XENOPUS LAEVIS;

EID: 70350101307     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24532     Document Type: Article

References (35)

1. Stubbs M, McSheehy PMJ, Griffiths JR, Bashford CL. Causes and consequences of tumour acidity and implications for treatment. Mol Med Today. 2000;6:15-19. (Pubitemid 30010232)
2. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004;4:891-899.
3. Ristow M. Oxidative metabolism in cancer growth. Curr Opin Clin Nutr Metab Care. 2006;9:339-345.
4. Kim J, Dang CV. Cancer's molecular sweet tooth and the Warburg effect. Cancer Res. 2006;66:8927-8930. (Pubitemid 44521105)
5. Pedersen PL. The cancer cell's "power plants" as promising therapeutic targets: an overview. J Bioenerg Biomembr. 2007;39:1-12.
6. Chen Z, Lu W, Garcia-Prieto C, Huang P. The Warburg effect and its cancer therapeutic implications. J Bioenerg Biomembr. 2007;39:267-274. (Pubitemid 47619379)
7. Ganapathy V, Thangaraju M, Prasad PD. Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacol Ther. 2009;121:29-40.
8. Warburg O. On the origin of cancer cells. Science. 1956; 123:309-314.
9. Ko YH, Pedersen PL, Geschwind JF. Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase. Cancer Lett. 2001;173:83-91.
10. Geschwind JF, Georgiades CS, Ko YH, Pedersen PL. Recently elucidated energy catabolism pathways provide opportunities for novel treatments in hepatocellular carcinoma. Expert Rev Anticancer Ther. 2004;4:449-457.
11. Mathupala SP, Ko YH, Pedersen PL. Hexokinase II: Cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene. 2006;25:4777-4786.
12. Acan NL, Ozer N. Modification of human erythrocyte pyruvate kinase by an active site-directed reagent: bromopyruvate. J Enzyme Inhib. 2001;16:457-464. (Pubitemid 34071689)
13. Geschwind JF, Ko YH, Torbenson MS, Magee C, Pedersen PL. Novel therapy for liver cancer: direct intra-arterial injection of a potent inhibitor of ATP production. Cancer Res. 2002;62:3909-3913. (Pubitemid 34791050)
14. Ko YH, Smith BL, Wang Y, et al. Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem Biophys Res Commun. 2004;324: 269-275. (Pubitemid 39311489)
15. Vali M, Liapi E, Kowalski J, et al. Intraarterial therapy with a new potent inhibitor of tumor metabolism (3-bromopyruvate): identification of therapeutic dose and method of injection in an animal model of liver cancer. J Vasc Interv Radiol. 2007;18:95-101. (Pubitemid 46628943)
16. Kim W, Yoon JH, Jeong JM, et al. Apoptosis-inducing antitumor efficacy of hexokinase II inhibitor in hepatocellular carcinoma. Mol Cancer Ther. 2007;6:2554-2562. (Pubitemid 47480421)
17. Cao X, Bloomston M, Zhang T, et al. Synergistic antipancreatic tumor effect by simultaneously targeting hypoxic cancer cells with HSP90 inhibitor and glycolysis inhibitor. Clin Cancer Res. 2008;14:1831-1839.
18. Li H, Myeroff L, Smiraglia D, et al. SLC5A8, a sodium transporter, is a tumor suppressor gene silenced by methylation in human colon aberrant crypt foci and cancers. Proc Natl Acad Sci U S A. 2003;100:8412-8417. (Pubitemid 36842559)
19. Ganapathy V, Thangaraju M, Gopal E, Itagaki S, Miyauchi S, Prasad PD. Sodium-coupled monocarboxylate transporters in normal tissues and in cancer. AAPS J. 2008;10:193-199.
20. Miyauchi S, Gopal E, Fei YJ, Ganapathy V. Functional identification of SLC5A8, a tumor suppressor down-regulated in colon cancer, as a Na(+)-coupled transporter for short-chain fatty acids. J Biol Chem. 2004;279:13293-13296. (Pubitemid 38468849)
21. Coady MJ, Chang MH, Charron FM, et al. The human tumour suppressor gene SLC5A8 expresses a Na(+)-monocarboxylate cotransporter. J Physiol. 2004;557:719-731.
22. Gopal E, Fei YJ, Sugawara M, et al. Expression of slc5a8 in kidney and its role in Na(+)-coupled transport of lactate. J Biol Chem. 2004;279:44522-44532. (Pubitemid 39430859)
23. Gopal E, Fei YJ, Miyauchi M, Zhuang L, Prasad PD, Ganapathy V. Sodium-coupled and electrogenic transport of B-complex vitamin nicotinic acid by slc5a8, a member of the Na/glucose cotransporter gene family. Biochem J. 2005;388:309-316. (Pubitemid 40732959)
24. Gopal E, Miyauchi S, Martin PM, et al. Transport of nicotinate and structurally related compounds by human SMCT1 (SLC5A8) and its relevance to drug transport in the mammalian intestinal tract. Pharm Res. 2007;24:575-584. (Pubitemid 46295162)
25. Gupta N, Martin PM, Prasad PD, Ganapathy V. SLC5A8 (SMCT1)-mediated transport of butyrate forms the basis for the tumor-suppressive function of the transporter. Life Sci. 2006;78:2419-2425.
26. Thangaraju M, Cresci G, Itagaki S, et al. Sodium-coupled transport of the short-chain fatty acid butyrate by SLC5A8 and its relevance to colon cancer. J Gastrointest Surg. 2008;12:1773-1782.
27. Thangaraju M, Gopal E, Martin PM, et al. SLC5A8 triggers tumor cell apoptosis through pyruvate-dependent inhibition of histone deacetylases. Cancer Res. 2006;66: 11560-11564. (Pubitemid 46094162)
28. Thangaraju M, Carswell KN, Prasad PD, Ganapathy V. Colon cancer cells maintain low levels of pyruvate to avoid cell death caused by inhibition of HDAC1/HDAC3. Biochem J. 2009;417:379-389.
29. Itagaki S, Gopal E, Zhuang L, et al. Interaction of ibuprofen and other structurally related NSAIDs with the sodium-coupled monocarboxylate transporter SMCT1 (SLC5A8). Pharm Res. 2006;23:1209-1216. (Pubitemid 43946143)
30. +) reveals the potential of the transporter as a drug target for cancer chemotherapy. Biochem J. 2008;414:343-355.
31. Gallagher SM, Castorino JJ, Wang D, Philp NJ. Monocarboxylate transporter 4 regulates maturation and trafficking of CD147 to the plasma membrane in the metastatic breast cancer cell line MDA-MB231. Cancer Res. 2007;67:4182-4189. (Pubitemid 46815064)
32. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer. 2001;1:194-202. (Pubitemid 33741894)
33. Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, Benz CC. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol. 2005;45:495-528. (Pubitemid 40261815)
34. Ullah MS, Davies AJ, Halestrap AP. The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1α-dependent mechanism. J Biol Chem. 2006;281:9030-9037.
35. Goffin J, Eisenhauer E. DNA methyltransferase inhibitors - state of the art. Ann Oncol. 2002;13:1699-1716. (Pubitemid 35439450)